Ubs Asset Management Americas Inc Arcutis Biotherapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 404,736 shares of ARQT stock, worth $8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
404,736
Previous 279,047
45.04%
Holding current value
$8 Million
Previous $4.36 Million
30.02%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ARQT
# of Institutions
240Shares Held
129MCall Options Held
407KPut Options Held
216K-
Suvretta Capital Management, LLC New York, NY11.5MShares$228 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$220 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$212 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$195 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$170 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.19B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...